Ipivivint (compound 38) 是一种有效的 CDC 样激酶 (CLK) 抑制剂，对 CLK2 和 CLK3 的EC50分别为 1 nM、7 nM。Ipivivint 抑制Wnt通路 (EC50=13 nM)。
| 生物活性 | Ipivivint (compound 38) is a potentCDC-like kinase(CLK)inhibitor withEC50s of 1 nM, 7 nM for CLK2 and CLK3, respectively. Ipivivint inhibitsWntpathway (EC50=13 nM)[1]. |
| IC50& Target[1] | CDK2 1 nM (EC50) | CDK3 7 nM (EC50) |
|
体外研究
(In Vitro) | Western Blot Analysis[1] | Cell Line: | SW480 cells | | Concentration: | 0.01~10 μM | | Incubation Time: | 1 hour | | Result: | Potently inhibited SRSF5/6 phosphorylation. |
Apoptosis Analysis[1] | Cell Line: | SW480 cells | | Concentration: | 0.01~10 μM | | Incubation Time: | 0.03 μM~3 μM | | Result: | Induced apoptosis. |
RT-PCR[1] | Cell Line: | HEK-293T cells | | Concentration: | 0.3~3 μM | | Incubation Time: | 1 hour | | Result: | Inhibited Wnt/β-catenin signaling induced by Wnt3a. |
Immunofluorescence[1] | Cell Line: | SW480 cells | | Concentration: | 0.3~10 μM | | Incubation Time: | 6 hours | | Result: | Increased nuclear speckle enlargement. |
|
体内研究
(In Vivo) | | Animal Model: | Foxn1 mice[1] | | Dosage: | 25 mg/kg | | Administration: | P.o. | | Result: | Potently inhibited tumor SRSF6 phosphorylation. |
|
| Clinical Trial | |
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : 3.33 mg/mL(7.17 mM;ultrasonic and warming and heat to 80℃) 配制储备液 | 1 mM | 2.1529 mL | 10.7643 mL | 21.5285 mL | | 5 mM | 0.4306 mL | 2.1529 mL | 4.3057 mL | | 10 mM | --- | --- | --- |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 |
m.cnreagent.com